All Stories

  1. The Molecular Interplay Between p53-Mediated Ferroptosis and Non-Coding RNAs in Cancer
  2. Emerging role of endogenous peptides encoded by non-coding RNAs in cancer biology
  3. TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)
  4. TLR4 Downregulation Identifies High-Risk HPV Infection and Integration in H-SIL and Squamous Cell Carcinomas of the Uterine Cervix
  5. Why so much uncertainty about adjuvant HPV vaccines after local treatment? Can the discrepancy between the positive statistical results and the scientific community doubts be solved?
  6. Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)
  7. Integrated plasma metabolomics and lipidomics profiling highlights distinctive signature of hepatocellular carcinoma in HCV patients
  8. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations
  9. Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
  10. Microorganisms-derived antigens for preventive anti-cancer vaccines
  11. Non-Classical HLA Class 1b and Hepatocellular Carcinoma
  12. Molecular mimicry and cancer vaccine development
  13. Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients
  14. The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development
  15. Antigenic molecular mimicry in viral-mediated protection from cancer: the HIV case
  16. The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development
  17. Antigenic molecular mimicry in viralmediated protection from cancer: the HIV case.
  18. Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data
  19. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)
  20. Molecular mimicry between tumor associated antigens and microbiota-derived epitopes
  21. Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis
  22. Molecular Mimicry Between Tumor Associated Antigens and Microbiota-derived Epitopes
  23. Profiling the HCV Immune Response in Patients with Chronic Liver Diseases and Hepatocellular Carcinoma by Peptide Microarray Analysis
  24. Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients
  25. Bimodal Antibody-Titer Decline Following BNT162b2 Mrna Anti-SARS-Cov-2 Vaccination In Healthcare Workers of The INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)
  26. Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
  27. Novel Molecular Targets for Hepatocellular Carcinoma
  28. Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides
  29. MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response
  30. Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma
  31. HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine
  32. Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).
  33. The Role of circRNAs in Human Papillomavirus (HPV)-Associated Cancers
  34. PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus‐related diseases
  35. Human Papillomavirus and Cancers
  36. The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic
  37. Detection of Human Papillomaviruses in the Nasopharynx of Breastfed Infants: New Findings and Meta-Analysis
  38. Modeling the epithelial-mesenchymal transition process in a 3D organotypic cervical neoplasia
  39. Detection of a large spectrum of viral infections in conjunctival premalignant and malignant lesions
  40. Covid‐19: Time for a paradigm change
  41. Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities
  42. Transoral robotic surgery in head and neck district: a retrospective study on 67 patients treated in a single center
  43. The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer
  44. SARS-CoV-2 RNA polymerase as target for antiviral therapy
  45. Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
  46. The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer
  47. Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy
  48. High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
  49. Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
  50. Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
  51. Updates on the Role of Molecular Alterations and NOTCH Signaling in the Development of Neuroendocrine Neoplasms
  52. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
  53. Corrigendum to “New vaccination strategies in liver cancer” [Cytokine Growth Factor Rev. 36 (2017) 125–129]
  54. Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma
  55. Uncovering “hidden” mutations in hepatocellular carcinoma: the use of droplet digital PCR to detect TERT promoter mutations
  56. Cancer Diagnostic and Predictive Biomarkers 2018
  57. Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
  58. The Role of Sensing Peptides in the Cross-talk between Microbiota and Human Cancer Cells
  59. Prevalence of “unclassified” HPV genotypes among women with abnormal cytology
  60. Cancer Vaccine for HCC
  61. Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers
  62. HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.
  63. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma
  64. Large deletion at the CDC73 gene locus and search for predictive markers of the presence of a CDC73 genetic lesion
  65. P-G5 Differential immune response to HCV peptides as cancer-progression biomarkers of HCV-infections
  66. The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma
  67. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma
  68. Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia
  69. Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents
  70. Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role
  71. Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting
  72. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
  73. New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology
  74. New vaccination strategies in liver cancer
  75. New cell block containing agarose for cytopathological diagnosis of tumor samples
  76. Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study
  77. Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma
  78. Use of adjuvants for immunotherapy
  79. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma
  80. An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
  81. Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference
  82. An Engineered Cell-Instructive Stroma for the Fabrication of a Novel Full Thickness Human Cervix Equivalent In Vitro
  83. Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma
  84. TERT promoter and CTNNB1 gene mutations represent cancer signatures specific for hepatitis B and hepatitis C related hepatocellular carcinoma
  85. MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients
  86. Cancer Diagnostic and Predictive Biomarkers 2016
  87. Virus-Like Particles
  88. Vaccine Approaches in Hepatocellular Carcinoma
  89. Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) – HEPAVAC
  90. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
  91. Immunological effects of a novel RNA-based adjuvant in liver cancer patients
  92. Abstract A046: Identification and validation of HCC-specific gene transcriptional signature for tumor antigen discovery
  93. Abstract A044: Immunological effects of a novel RNA-based adjuvant in liver cancer patients
  94. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma
  95. Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery
  96. Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
  97. Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer
  98. Combinatorial immunotherapy strategies for hepatocellular carcinoma
  99. Cancer vaccines for hepatocellular carcinoma: future directions
  100. Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation
  101. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections
  102. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR
  103. A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice
  104. Infectious Agents and Cancer reviewer acknowledgement 2015
  105. A-108 Viral and cellular biomarkers in HPV-related cancers
  106. Functional characterization of biodegradable nanoparticles as antigen delivery system
  107. Systems Biology Approach for Cancer Vaccine Development and Evaluation
  108. Developments in cancer vaccines for hepatocellular carcinoma
  109. An overview of new biomolecular pathways in pathogen-related cancers
  110. Cancer biomarkers
  111. Cellular prognostic markers in hepatocellular carcinoma
  112. Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer
  113. Brooke-Spiegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: Cytologic findings on fine-needle sample and description of a novel mutation of the CYLD gene
  114. Correction: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases
  115. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model
  116. Tobacco Smoke Activates Human Papillomavirus 16 p97 Promoter and Cooperates with High-Risk E6/E7 for Oxidative DNA Damage in Lung Cells
  117. Combined Papillary and Mucoepidermoid Carcinoma of the Thyroid Gland: a Possible Collision Tumor Diagnosed on Fine-Needle Cytology. Report of a Case with Immunocytochemical and Molecular Correlations
  118. Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis
  119. Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer
  120. Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases
  121. Follicular thyroid carcinoma with skull metastases
  122. Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies
  123. Cancer Diagnostic and Predictive Biomarkers 2015
  124. Identification of Human Herpesvirus 8 Sequences in Conjunctiva Intraepithelial Neoplasia and Squamous Cell Carcinoma of Ugandan Patients
  125. The XIX century smallpox prevention in Naples and the risk of transmission of human blood-related pathogens
  126. Virus-like Particles
  127. HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2
  128. CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
  129. Antigen-specific vaccines for cancer treatment
  130. Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study
  131. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix
  132. HPV-related oropharyngeal cancers: From pathogenesis to new therapeutic approaches
  133. Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines
  134. Systems vaccinology for cancer vaccine development
  135. 150 Carcinogenesis of HPV
  136. Human Papillomavirus Infection and Cervical Neoplasia among Migrant Women Living in Italy
  137. Emotional false memories in children with learning disabilities
  138. CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity
  139. The Functional Role of MnSOD as a Biomarker of Human Diseases and Therapeutic Potential of a New Isoform of a Human Recombinant MnSOD
  140. Developments in virus-like particle-based vaccines for HIV
  141. Duodenal gangliocytic paraganglioma, a rare entity among GEP-NET: a case report with immunohistochemical and molecular study
  142. Cancer Diagnostic and Predictive Biomarkers
  143. Electrochemotherapy as “new standard of care” treatment for cutaneous Kaposi's sarcoma
  144. Corrigendum to: “Challenges in cancer vaccine development for hepatocellular carcinoma” [J Hepatol 2013;59:897–903]
  145. Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach
  146. Virus-like particle vaccines for the prevention of human papillomavirus infection
  147. Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection
  148. Cancer-Associated CD43 Glycoforms as Target of Immunotherapy
  149. Challenges in cancer vaccine development for hepatocellular carcinoma
  150. VLPs and particle strategies for cancer vaccines
  151. New developments in cancer vaccines
  152. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections
  153. Kaposi’s sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies
  154. High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer
  155. Infections and cancer: debate about using vaccines as a cancer control tool
  156. Development of a stable insect cell line constitutively expressing rotavirus VP2
  157. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review
  158. Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis
  159. Developments in virus-like particle-based vaccines for HIV
  160. The application of virus-like particles to human diseases
  161. Lung cancer diagnosis on ovary mass: a case report
  162. Massive edema of ovary with cytogenetic alteration of chromosome 12q13-15 in adolescent patient: a case report
  163. Expression Analysis of SPARC/Osteonectin in Oral Squamous Cell Carcinoma Patients: From Saliva to Surgical Specimen
  164. Viral and Cellular Biomarkers in the Diagnosis of Cervical Intraepithelial Neoplasia and Cancer
  165. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
  166. Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer
  167. Identification and sequence analysis of a novel human leukocyte antigen alleleB*51:141
  168. Oncolytic virus therapies
  169. Multiparametric Analyses of Human PBMCs Loaded Ex Vivo with a Candidate Idiotype Vaccine for HCV-Related Lymphoproliferative Disorders
  170. HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens
  171. Immunogenomics approaches for vaccine evaluation
  172. Functional Interaction between Human Papillomavirus Type 16 E6 and E7 Oncoproteins and Cigarette Smoke Components in Lung Epithelial Cells
  173. Advances in viral oncology research: summary of the 3rd International Meeting
  174. Immunogenicity of HIV Virus-Like Particles in Rhesus Macaques by Intranasal Administration
  175. Characterization of the Human Papillomavirus (HPV) Integration Sites into Genital Cancers
  176. Quality of life, lifestyle behavior and employment experience: A comparison between young and midlife survivors of gynecology early stage cancers
  177. Axillary node metastasis from differentiated thyroid carcinoma with hürthle and signet ring cell differentiation. A case of disseminated thyroid cancer with peculiar histologic findings
  178. Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients
  179. Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization
  180. Effects of adjuvants on IgG subclasses elicited by virus-like Particles
  181. HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies
  182. Innate immunity and hepatitis C virus infection: a microarray’s view
  183. Assessment ofChlamydia trachomatisinfection among Eastern European and West African women immigrants in South Italy
  184. Developments in virus-like particle-based vaccines for infectious diseases and cancer
  185. Plant-derived anti-HIV-1 proteins
  186. Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?
  187. Can HIV p24 Be a Suitable Scaffold for Presenting Env Antigens?
  188. PlantPIs – An Interactive Web Resource on Plant Protease Inhibitors
  189. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins
  190. HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line
  191. High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy
  192. New adjuvants in evolving vaccine strategies
  193. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix
  194. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma in Italian patients
  195. Systems biology applied to vaccine and immunotherapy development
  196. Metastatic breast carcinoma to parathyroid adenoma on fine needle cytology sample: Report of a case
  197. Translating Tumor Antigens into Cancer Vaccines
  198. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi’s sarcoma in African and Caucasian patients
  199. Immune Signatures and Systems Biology of Vaccines
  200. Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system
  201. Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy
  202. Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches
  203. Human papillomavirus infection in urine samples from male renal transplant patients
  204. Virus-Like Particles as Particulate Vaccines
  205. Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era
  206. Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders
  207. FEZ1/LZTS1 protein expression in ovarian cancer
  208. Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies
  209. Virus-like particle vaccines and adjuvants: the HPV paradigm
  210. Adhesion molecules and p16 expression in endocervical adenocarcinoma
  211. Molecular immune signatures of HIV-1 vaccines in human PBMCs
  212. Short Communication: Limited Induction of IL-10 in PBMCs from HIV-Infected Subjects Treated with HIV-VLPs
  213. 183 Morphogenomic immune responsiveness to preventive/therapeutic vaccines
  214. 210 Peripheral blood mononuclear cells activated by HIV-VLPs in correlation with HIV-1 seropositivity status
  215. Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy
  216. Fine-needle cytology of metastatic endometrioid neoplasms: Experience with eight cases
  217. Detection of mucosal and cutaneous human papillomaviruses in oesophagitis, squamous cell carcinoma and adenocarcinoma of the oesophagus
  218. Unsung Hero Robert C. Gallo
  219. Spontaneous infarction of pleomorphic adenoma: Report of a case simulating malignancy on fine-needle cytology sample
  220. Sclerosing polycystic adenosis of the parotid gland: Report of one case diagnosed by fine-needle cytology with in situ malignant transformation
  221. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma
  222. P12-03. Generation of novel recombinant HIV-1 glycoproteins for expression on virus like particles
  223. P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies
  224. TP53 Codon 72 Polymorphism in Classic, Endemic and Epidemic Kaposi’s Sarcoma in African and Caucasian Patients
  225. A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women
  226. Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)-Infected Subjects, as Activated by HIV Virus-Like Particles
  227. Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma
  228. Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women
  229. Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco
  230. Clear-cell myoepithelial carcinoma of the salivary glands: A clinicopathologic, immunohistochemical, and ultrastructural study of two cases involving the submandibular gland with review of the literature
  231. Correction
  232. Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation
  233. Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy
  234. HIV Type 1 Subtype A Epidemic in Injecting Drug User (IDU) Communities in Iran
  235. DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
  236. Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications
  237. Human papillomavirus genotypes and HPV16 variants in penile carcinoma
  238. Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example
  239. Structured particles for antigen presentation
  240. Genetic and Phylogenetic Characterization of Structural Genes from Non-B HIV-1 Subtypes in Italy
  241. Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses
  242. Evaluating the role of human papillomaviruses in conjunctival neoplasia
  243. Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population
  244. Baculovirus-Derived HIV-1 Virus-Like Particles (VLP) Activate Dendritic Cells and Are Cross-Presented to Induce In Vitro T-Cell Response
  245. Induction of Systemic and Mucosal Cross-Clade Neutralizing Antibodies in BALB/c Mice Immunized with Human Immunodeficiency Virus Type 1 Clade A Virus-Like Particles Administered by Different Routes of Inoculation
  246. Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance
  247. TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda
  248. Screening of HIV-1 Isolates by Reverse Heteroduplex Mobility Assay and Identification of Non-B Subtypes in Italy
  249. Human papillomaviruses and cervical lesions in the Italian population
  250. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer
  251. Kaposi's sarcoma: aetiopathogenesis, histology and clinical features
  252. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A
  253. High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A
  254. Identification and functional analysis of sequence rearrangements in the long control region of human papillomavirus type 16 Af-1 variants isolated from Ugandan penile carcinomas
  255. The Uganda study on HPV variants and genital cancers
  256. Warthin-like tumour of the thyroid gland: RET/PTC expression indicates it is a variant of papillary carcinoma
  257. Sequence Note: A Novel Glycoprotein 120 Sequence from an HIV Type 1 Isolate of the A Clade Identified in North Uganda
  258. Sequence variations and viral genomic state of human papillomavirus type 16 in penile carcinomas from Ugandan patients.
  259. Post-operative complications after completion thyroidectomy for differentiated thyroid cancer
  260. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies
  261. Analysis of HIV-1 env gene V3 loop sequence in a southern Italian cohort of intravenous drug users
  262. Human Immunodeficiency Virus Type 1 tat Gene Enhances Human Papillomavirus Early Gene Expression
  263. Human papillomavirus (hpv) DNA in penile carcinomas and in two cell lines from high-incidence areas for genital cancers in Africa
  264. Role of HIV as Cofactor in HPV Oncogenesis: In vitro Evidences of Virus Interactions
  265. Role of HIV-1 Tat in the Pathogenesis of AIDS-Associated Kaposi�s Sarcoma1
  266. V3 Region Genotyping of HIV Isolates in Northern Uganda: Heteroduplex Mobility Assay, Nucleotide Sequence and Phylogenese Analysis